

# Resource Summary Report

Generated by [nidm-terms](#) on Jul 29, 2026

## IARC TP53 Database

RRID:SCR\_007731

Type: Tool

---

### Proper Citation

IARC TP53 Database (RRID:SCR\_007731)

---

### Resource Information

**URL:** <http://p53.iarc.fr/>

**Proper Citation:** IARC TP53 Database (RRID:SCR\_007731)

**Description:** The IARC TP53 Mutation Database compiles all TP53 gene variations identified in human populations and tumor samples. Data are compiled from the peer-reviewed literature and from generalist databases. The following datasets are available: # TP53 somatic mutations in sporadic cancers # TP53 germline mutation in familial cancers # Common TP53 polymorphisms identified in human populations # Functional and structural properties of P53 mutant proteins # TP53 gene status in human cell-lines # Mouse-models with engineered TP53 The database includes various annotations on the predicted or experimentally assessed functional impact of mutations, clinicopathologic characteristics of tumors and demographic and life-style information on patients. The database is meant to be a source of information on TP53 mutations for a broad range of scientists and clinicians who work in different research areas: # Basic research, to study the structural and functional aspects of the p53 protein # Molecular pathology of cancer, to understand the clinical significance of mutations identified in cancer patients # Molecular epidemiology of cancer, to analyze the links between specific exposures and mutation patterns and to make inferences about possible causes of cancer # Molecular genetics, to analyze genotype/phenotype relationships

**Abbreviations:** IARC TP53 Database

**Resource Type:** data or information resource, database

**Resource Name:** IARC TP53 Database

**Resource ID:** SCR\_007731

**Alternate IDs:** nif-0000-03006

**Old URLs:** <http://www-p53.iarc.fr/index.html>

**Record Creation Time:** 20220129T080243+0000

**Record Last Update:** 20260729T044152+0000

---

## Ratings and Alerts

No rating or validation information has been found for IARC TP53 Database.

No alerts have been found for IARC TP53 Database.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 153 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [nidm-terms](#) .

Perachino M, et al. (2025) Different activity and toxicity of immunotherapy in monozygotic twins diagnosed with early triple-negative breast cancer: a case report. Therapeutic advances in medical oncology, 17, 17588359241297565.

Fawaz S, et al. (2024) Evaluation of clonal hematopoiesis and mosaic loss of Y chromosome in cardiovascular risk: An analysis in prospective studies. eLife, 13.

Li C, et al. (2024) Unveiling correlations between aristolochic acids and liver cancer: spatiotemporal heterogeneity phenomenon. Chinese medicine, 19(1), 132.

Cordova RA, et al. (2024) Coordination between the eIF2 kinase GCN2 and p53 signaling supports purine metabolism and the progression of prostate cancer. Science signaling, 17(864), eadp1375.

Song R, et al. (2024) Clinical Features of Li-Fraumeni Syndrome in Korea. Cancer research and treatment, 56(1), 334.

Kibe Y, et al. (2024) Pediatric-type high-grade gliomas with PDGFRA amplification in adult patients with Li-Fraumeni syndrome: clinical and molecular characterization of three cases. Acta neuropathologica communications, 12(1), 57.

Thatikonda V, et al. (2023) Comprehensive analysis of mutational signatures reveals distinct patterns and molecular processes across 27 pediatric cancers. Nature cancer, 4(2), 276.

Huang Q, et al. (2023) Evaluating the prognostic significance of p53 and TP53 mutations in HPV-negative hypopharyngeal carcinoma patients: a 5-year follow-up retrospective study. BMC cancer, 23(1), 324.

- Stružinská I, et al. (2023) A comprehensive molecular analysis of 113 primary ovarian clear cell carcinomas reveals common therapeutically significant aberrations. *Diagnostic pathology*, 18(1), 72.
- Rana M, et al. (2022) A ferrocene-containing nucleoside analogue targets DNA replication in pancreatic cancer cells. *Metallomics : integrated biometal science*, 14(7).
- Cafforio L, et al. (2022) Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia. *Haematologica*, 107(1), 334.
- Hassell DS, et al. (2021) Chemical rescue of mutant proteins in living *Saccharomyces cerevisiae* cells by naturally occurring small molecules. *G3 (Bethesda, Md.)*, 11(9).
- Martinho MS, et al. (2021) Chaperones and Ubiquitin Ligases Balance Mutant p53 Protein Stability in Esophageal and Other Digestive Cancers. *Cellular and molecular gastroenterology and hepatology*, 11(2), 449.
- Tong X, et al. (2021) Identification of a druggable protein-protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1. *The Journal of biological chemistry*, 296, 100098.
- Raad S, et al. (2021) Blood functional assay for rapid clinical interpretation of germline TP53 variants. *Journal of medical genetics*, 58(12), 796.
- Chen D, et al. (2021) iPLA2 $\gamma$ -mediated lipid detoxification controls p53-driven ferroptosis independent of GPX4. *Nature communications*, 12(1), 3644.
- Kobar K, et al. (2021) Zebrafish Cancer Predisposition Models. *Frontiers in cell and developmental biology*, 9, 660069.
- Vodicka P, et al. (2021) The Interactions of DNA Repair, Telomere Homeostasis, and p53 Mutational Status in Solid Cancers: Risk, Prognosis, and Prediction. *Cancers*, 13(3).
- Denney AS, et al. (2021) Selective functional inhibition of a tumor-derived p53 mutant by cytosolic chaperones identified using split-YFP in budding yeast. *G3 (Bethesda, Md.)*, 11(9).
- Lai ZY, et al. (2021) Gain-of-Function Mutant TP53 R248Q Overexpressed in Epithelial Ovarian Carcinoma Alters AKT-Dependent Regulation of Intercellular Trafficking in Responses to EGFR/MDM2 Inhibitor. *International journal of molecular sciences*, 22(16).